Promomed Group begins joint work with Skolkovo Foundation

Within the framework of the XXV St. Petersburg International Economic Forum, a cooperation agreement was signed between Promomed Group of Companies, Biochemist JSC and the Skolkovo Foundation in order to begin joint work in the development of biotechnological drugs, new dosage forms, improved methods for synthesizing pharmaceutical substances, conducting and coordinating a full range of preclinical and clinical studies and the potential creation of modern a research center at the site of the regional operator of the Foundation in the Republic of Mordovia*.

Peter Bely, Chairman of the Board of Directors of Promomed Group, commented on the joint decision to work in the field of research and development with the Foundation for the Development of the Center for the Development and Commercialization of New Technologies: "A new era in medicine has arrived – biotechnologies, RNA therapy, domestic substances of the highest quality - the answer to the challenges of today. And we will answer them together with the leader of innovation, the Skolkovo Foundation. We see great prospects in joint work on the modeling of candidate molecules for medicinal products, the development of methods for the synthesis of pharmaceutical substances, optimization and improvement of technologies for the production of APIs and finished dosage forms, and in other areas. The critical challenges of medicine, which Promomed traditionally works on, require the consolidation of the best forces."

As the Executive Director of JSC Biochemik (part of the Promomed Group) noted after the solemn signing Dmitry Zemskov, this agreement is not exactly typical, it is filled with specifics. "This reflects our most determined intentions to achieve our goals. We are already discussing in detail with our partners from Skolkovo the possibility of establishing a research center based on the regional operator of the Skolkovo Foundation in the Republic of Mordovia, and we are also considering the possibility of obtaining resident status for JSC Biochemik. 

I think we will see the results of this collaboration soon. And patients will receive affordable high—quality drugs," Zemskov said.

Igor Drozdov, Chairman of the Board of the Skolkovo Foundation: "One of the priorities of the state program for the Development of the Pharmaceutical and Medical Industry is import independence. Skolkovo aims to achieve this goal within the framework of cooperation with leading domestic pharmaceutical companies. We are confident that the partner center based on our regional operator in Mordovia will benefit in the creation of medicines for the residents of our country."

The creation of a Research Partnership Center (RPI) is of great strategic importance for the implementation of the state program "Development of the pharmaceutical and medical industry", which is designed to solve one of the most important tasks — the country's independence from imports. A cluster of this kind will provide an opportunity to conduct and coordinate a full range of preclinical and clinical studies to bring promising developments to the stage of a ready-to-commercialize product.